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ABSTRACT:
Introduction: Prostate cancer (PC) is the most common male
cancer in the USA. When comparing the incidence and mortality
rates of PC, the Surveillance Epidemiology and End Results data of

65–74 years. Appalachian Kentucky patients had a higher Gleason
score, higher prostate specific antigen (PSA), more aggressive
histologic grade, more distant disease, higher comorbidity score,

2005–2014 show that Appalachian Kentucky had a lower incidence
(113/100 000 v 137/100 000) but a higher mortality rate (23.8% v
21.8%) when compared to non-Appalachian Kentucky. The aim of
this study was to further characterize the survival disparities of PC

lower education, and higher poverty compared to patients from
non-Appalachian Kentucky. There was a 5-year survival difference
between Appalachian Kentucky and non-Appalachian Kentucky in
unadjusted analysis (p<0.001) that disappeared after adjusting

between Appalachian and non-Appalachian Kentucky.
Methods: All stages of PC patients diagnosed between 2007 and
2011 were collected through the Kentucky Cancer Registry.
Baseline characteristics and survival outcomes were compared

with Cox regression analysis (p=0.4). However, worsened survival
was still seen with higher Gleason score, higher PSA, distant stage
disease, higher Charlson comorbidity index, and very low high
school education (p<0.001).

between Appalachian Kentucky and non-Appalachian Kentucky,
using Pearson χ2 and Cox regression analyses in this populationbased analysis.
Results: Of 12 871 patients studied, 3482 (26.8%) were from
Appalachian Kentucky whereas 8489 (73.2%) were from non-

Conclusion: In this population-based analysis, this study shows a
significant difference in PC survival between Appalachian and nonAppalachian Kentucky. The difference was not related to
geographic location, but rather to high comorbidity score, high
poverty rate, and low education. Additional research is needed to

Appalachian Kentucky. Caucasians predominated in both
groups. Most Appalachian Kentucky patients were aged

understand the healthcare restraints for Appalachian Kentucky.

Keywords:
prostate cancer, Appalachian Kentucky, Kentucky Cancer Registry, non-Appalachian Kentucky, survival disparities, USA.

FULL ARTICLE:
Introduction
Cancer continues to be one of the top five leading causes of death
globally, and specifically ranks second as the leading cause of
mortality in the USA1. In particular, individuals living in nonmetropolitan (rural) regions of the USA have higher cancer
mortality rates than persons living in metropolitan (urban) regions
even though nationwide cancer mortality rates are 20% lower2. Yao
et al found that cancer mortality rates were 36% higher in rural
Appalachian Kentucky compared to West Virginia, the only state
wholly designated as Appalachian3.
As of July 2016, approximately 25.6 million or 8% of the US
population live in the 13-state Appalachian region of the USA4. Of
those individuals residing in Appalachia, 16 million live in
metropolitan areas compared to 7 million who live in nonmetropolitan areas. The Appalachian region is divided into five
subregions: Northern, North Central, Central, South Central, and
Southern4. The region follows the spine of the Appalachian
Mountains, from New York to Mississippi, and comprises
420 counties in 13 states. The 54 primarily rural counties
designated as Appalachian in the state of Kentucky are considered
part of Central Appalachia4.
Over 1.1 million people live in Appalachian Kentucky and
3.2 million live in non-Appalachian Kentucky4. As of July 2016,
Caucasians were the predominant racial group in both
Appalachian (94.7%) and non-Appalachian (81.5%) Kentucky.
Individuals residing in non-Appalachian Kentucky are more likely
to have higher levels of education than their Appalachian
counterparts. For example, approximately 26% of nonAppalachians versus 14.3% of Appalachians have a bachelor’s

degree. From 2012 to 2016, the median per capita income for
Appalachian Kentucky residents was $19,212 and 11% of the
population were below 50% of the federal poverty level; this is in
comparison to a median per capita income of $26,835 in nonAppalachia, and only 7% of residents below 50% of the poverty
level4.
Cancer incidence varies among the different regions of Appalachia.
For example, Wingo et al investigated the cancer incidence in
Appalachia from 2001 to 2003 and found that the incidence of
prostate cancer (PC) was higher in Northern Appalachia compared
to Central Appalachia and that this difference was related to
socioeconomic conditions5. In contrast to these findings, a study
by Wilson et al from 2004 to 2011 showed that Southern
Appalachia had a higher incidence of PC than Northern or Central
Appalachia6. The authors hypothesized that the findings might be
related to the demographics of the population: approximately 30%
of the Appalachian African American population lived in the
Southern region compared to 15% in Central Appalachia and 17%
in the Northern region6. Antwi et al. demonstrated that PC-specific
mortality was significant in the Appalachian region compared to
the non-Appalachian area of the USA7.
Despite being the most commonly diagnosed malignancy in men
in the USA1, and differing findings from across the Appalachian
region, PC in Appalachian Kentucky has not been well studied.
Therefore, the purpose of this study was to conduct a populationbased survival analysis of PC focused on comparisons between
Appalachian Kentucky and non-Appalachian Kentucky.

Methods

histology, and treatment type.

Data sources

Statistical analysis

This retrospective population-based study extracted records of all
PC patients residing in Kentucky from the Kentucky Cancer
Registry (KCR) from 2007 to 2011. The KCR is a population-based

Descriptive analysis of demographic and clinical factors was
performed. Bivariate analyses with χ2 tests were performed to
examine the association between Appalachian status and other

registry, awarded the highest level of certification by the North
American Association of Central Cancer Registries for objective
evaluation of completeness, accuracy, and timeliness every year
since 1997 and is also part of the National Cancer Institute’s
Surveillance, Epidemiology and End Results (SEER) program. The

covariates. Kaplan–Meier plots and log-rank tests were conducted
for survival analysis. Stepwise Cox regression analyses were
performed to estimate the effect of Appalachian status and other
clinical and demographic variables for both observed survival and
cause-specific survival. All analyses were performed using

KCR also links its database to 2011 health administrative claims for
additional comorbidity and treatment information. The linked data
includes claims from Medicare, Medicaid, and private insurance
companies (eg Humana, Blue Cross), thereby providing a more

Statistical Analysis Software v9.4 (SAS Institute, Inc.,
http://www.sas.com). All statistical tests were two-sided with
p<0.05 used to identify statistical significance.

complete review of treatment procedures, medical comorbidities,
and insurance-related variables across all age groups.

Ethics approval

Study population and variables

University of Kentucky (17-0533-P1G).

The study included all PC patients residing in Kentucky between

Results

2007 and 2011 and included in the linked KCR data. To limit biases,
only first primary cancer cases with a minimum age of 20 years
were included. To minimize selection bias, cases extracted through
death certificate and autopsy cases were excluded. A total of
12 971 out of 14 680 PC cases met selection criteria and were used
for data analysis. If a patient had treatment-related claims, such as
radiation, chemotherapy, and hormone treatment, captured
1 month prior to their cancer diagnosis up to 1 year after
diagnosis, this claims information was used to augment KCR
treatment data.
Prostate-specific antigen (PSA) level at diagnosis was defined
based on the patient’s laboratory value and recategorized as 1–10,
10–20 or >20. Gleason score at diagnosis was grouped as <6, 6–8,
>8–10 and unknown. The Charlson comorbidity index (CCI) was
calculated based on the KCR-linked claims data and represented
the 1–12-month time period prior to cancer diagnosis8. The CCI
variable was categorized as 0, 1, 2 and ≥3; it was treated as
unknown if a case did not have 12 months of continuous insurance
coverage prior to the cancer diagnosis.
Urban/rural status was based on the US Department of
Agriculture’s 2003 Urban–Rural Continuum Codes, with 1–3
defined as ‘urban’ and 4–9 as ‘rural’9. The county-level Appalachian
status was based on definitions from the Appalachia Regional
Commission10. Percentage below poverty was defined based on
quantiles of census tract level, with less than 6.51% as ‘low’,
>6.51–12.31% as ‘moderate’, >12.31–20.17% as ‘high’, and >20.17
as ‘very high’. Ascertainment of a high school education was also
defined based on quantiles of census tract level, with less than
66.12% as ‘very low’, >66.12–75.54% as ‘low’, >75.54–85.38% as
‘moderate’, and >85.38% as ‘high’. Other study demographic and
clinical variables included age at diagnosis, year at diagnosis, race,
smoking history, insurance status, survival status, stage at
diagnosis, number of lymph nodes examined, tumor size, tumor

The study was approved by the Institutional Review Board at the

A total of 12 971 individuals diagnosed with PC between January
2007 and December 2011 were identified. As presented in Table 1,
73.2% of these cases were from non-Appalachian Kentucky
counties and 26.8% were from Appalachian counties. The most
common age group in non-Appalachia was 50–64 years and in
Appalachia 65–74 years. Caucasian was the predominant race in
both geographic regions. Compared to their non-Appalachian
Kentucky counterparts, more PC patients in Appalachia were
uninsured (1.8%), lived in rural areas (87.8%), were rated with an
ascertainment of ‘very low’ high school education (65.9%), and
associated with ‘very high’ poverty (68%) (Table 2). Clinically, PC
patients from Appalachia were more likely to present with a
Gleason score of 8–10 (16.8%) and with a PSA level >20 (12.3%),
be diagnosed with stage 4 disease (6.9%), have poorly
differentiated histology (53.5%), and have a CCI>3 (5.4%)
compared to non-Appalachian patients. Appalachian PC patients
had higher rates of no treatment, radiation therapy only, hormone
treatment only, and combined radiation/hormone treatment.
In an unadjusted survival analysis, there was a 5-year overall
survival difference between Appalachian Kentucky and nonAppalachian Kentucky PC cases (p<0.001) (Fig1). After controlling
for demographic and clinical variables in a Cox regression model,
no survival difference was seen between Appalachian Kentucky
and non-Appalachian Kentucky PC cases (p=0.4) (Table 2).
However, statistical significance in survival was observed among
other variables such as age at diagnosis, insurance, smoking status,
Gleason score, PSA, CCI, treatment, and education (Table 2).
Despite a 5-year lower incidence of PC in Appalachia as compared
to non-Appalachian Kentucky, Kentucky, and the USA, the authors
observed a significantly higher 5-year PC mortality rate in
Appalachian Kentucky compared to non-Appalachian Kentucky as
well as the USA as a whole (Table 3).

Table 1: Demographic and cancer attributes for patients diagnosed with prostate cancer in Kentucky from 2007 to 2011:
comparison between Appalachian and non-Appalachian Kentucky

Table 2: Estimates of Appalachian status and other covariates in a Cox-regression model

Table 3: Age-adjusted incidence and mortality rates of prostate cancer in Appalachian Kentucky, non-Appalachian Kentucky
and USA, 2010–2014

Figure 1: Kaplan–Meier plots by Appalachian status.†
Discussion
PC is the most common malignancy among men in the USA.
Interestingly, when comparing the PC incidence and mortality rates

those with a higher number of comorbidities experienced lower
survival as all these factors are associated with poorer overall
health and negative cancer-related outcomes.

using SEER data from 2005 to 2014, findings suggest that
Appalachian Kentucky had a lower incidence but a higher mortality

In order to improve PC outcomes in Appalachian Kentucky, more
research and educational programming are needed at multiple

rate compared to non-Appalachian Kentucky and the USA. This
population-based study based on PC data from the KCR from 2007

levels, including the patient and their family. Schoenberg et al
conducted a community survey to address cancer disparities in

to 2011 showed that men in Appalachian Kentucky have a
significantly higher mortality rate of PC compared to their

Appalachian Kentucky and identified three challenges: (1)
inadequate awareness of the need for cancer prevention and

counterparts in non-Appalachian Kentucky. This disparity in PC
mortality may be primarily attributed to lower socioeconomic
status, lower levels of education, increased risk behaviors and

screening, (2) insufficient access to services across the cancer
continuum and (3) concern for lack of privacy15. Barriers related to
the lack of privacy comprise personal attitudes such as fear or

presence of comorbidities, and fewer available health resources in

discomfort, personal (negative) beliefs about cancer, and

rural Appalachian Kentucky11. However, the disparity can’t be
explained by geography alone. Interestingly, Appalachian PC
patients were also more likely to present with advanced clinical

misperceptions about health care and limited patient-centered
communication15. Coyne et al conducted a study that explored
cultural norms in rural Appalachia about health and concluded that

cases, including higher Gleason scores, higher PSA values, stage 4
disease, and poorly differentiated tumor histology, which may have
impacted overall survival.

rural Appalachian residents have a sense of place, strong family
ties, and a strong spiritual belief16. Increased awareness of family
cancer history, adopting a healthy lifestyle, securing social and
familial support, and engaging in informed and shared decision

Uninsured patients had worse outcomes compared to individuals
covered by Medicaid, and Medicaid patients fared worse compare
to men covered by Medicare. Uninsured and low-income PC
patients with Medicaid may have inadequate access to primary,
secondary, and tertiary-related health care services and experience
variations in treatments12,13. Additionally, these PC patients may
face other barriers to care such as limited transportation and

making between PC patients and providers – along with alleviating
fear and correcting misperceptions – can empower men to take
control of their health.

financial distress related to their diagnosis. PC patients who did
not finish high school had an increased risk of dying compared to

systems, clinicians, and support teams to deliver quality PC care.
For example, the University of Kentucky Markey Cancer Center

those who had a bachelor’s degree or more. Blackley et al
suggested that education and income status are associated with
higher cancer mortality and suggested that improving education
levels could result in decreased cancer mortality rate in
Appalachia14.

(MCC) is the only National Cancer Institute-designated cancer
center in Kentucky17. MCC provides high quality clinical and
psychosocial cancer care, along with the opportunity for patients
to participate in clinical trials. The MCC also supports an Affiliate
Network, a collaborative of 26 community hospitals across

As expected, this study demonstrates that men aged over 75 years,
those with higher Gleason scores and PSA values, smokers, and

Not only should there be efforts to educate Appalachian
Kentuckians at the individual patient and family levels, but
interventions are also needed to train and empower healthcare

Kentucky18, including Appalachia, focused on increasing access to
oncology education, training, clinical trials, and screening services,

all with the mission of providing evidence-based, quality cancer
care close to home.

PC survival disparities between Appalachian and non-Appalachian
Kentucky and contributes to a related gap in the literature.

Improvements in PC screening could contribute to improvements
in PC survival in Appalachian Kentucky as this population is more
likely to have more advanced disease at the time of diagnosis.
Similarly, improvements in access to insurance, primary care

Conclusion

providers, urology and oncology providers, and supportive care
services are needed in the region. More research is also needed to
understand the advanced clinical presentation of PC in Appalachia,
including related behavioral, environmental, genetic, and cultural
factors.
A limitation to the current study is its design as a retrospective
population-based data analysis; in addition, the data is dependent
on accurate coding in the KCR database. For example, data for
some of the variables such as race, smoking status, PSA level and
Gleason score are missing. Despite these limitations, this study
presents a novel and comprehensive population-based analysis of

In this population-based analysis, there was a significant difference
in PC survival between men from Appalachian Kentucky and that
of men from non-Appalachian Kentucky. This study supports the
concept that patients from Appalachia generally present with later
stage, more aggressive disease. This is likely most impacted by the
differences in socioeconomic and educational backgrounds of the
Appalachian and non-Appalachian population that may delay
diagnosis and care. Long-term efforts to improve cancer care in
this population must focus on barriers to early diagnosis and
treatment. Improvements in socioeconomic status and education
levels, which are independent predictors of poor outcomes in this
population, must be achieved in order to see a decrease in PC
mortality rates in Appalachian Kentucky.
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